Lookup NU author(s): Dr Eleri Williams,
Dr Janet Berrington
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Screening for a condition should only be undertaken if certain strict criteria are met. Congenital CMV (cCMV) is a leading cause of sensorineuronal hearing loss (SNHL) and meets many of these criteria, but is not currently screened for in the UK. Ganciclovir reduces CMV-induced progressive SNHL if treatment is begun in the first month of life. The Newborn Hearing Screening Programme (NHSP) has been shown to identify SNHL at the earliest possible age. The potential of integrating screening for cCMV into the NHSP is discussed to consolidate the link between screening, early diagnosis and management.Conclusion The early diagnosis and treatment of cCMV may prevent a small proportion of late SNHL. In the absence of any screening programme, we provide evidence that clinically targeted screening through the NHSP is a potential option in the UK, enhancing the diagnostic pathway and enabling appropriate early treatment to reduce long-term morbidity.
Author(s): Kadambari S, Luck S, Davis A, Williams EJ, Berrington J, Griffiths PD, Sharland M
Publication type: Article
Publication status: Published
Journal: Acta Paediatrica
Print publication date: 01/10/2013
Online publication date: 08/08/2013
Acceptance date: 25/06/2013
ISSN (print): 0803-5253
ISSN (electronic): 1651-2227
Altmetrics provided by Altmetric